title: Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial.
abstract: OBJECTIVE
  To compare fertilization, implantation and pregnancy rates in donor oocyte cycles triggered for final oocyte maturation with either human chorionic gonadotropin (hCG) or gonadotropin releasing hormone (GnRH) agonist in the same donor population in two sequential stimulation cycles.
  
  
  METHODS
  Prospective randomized cross-over trial.
  
  
  METHODS
  Private infertility clinic.
  
  
  METHODS
  Eighty-eight stimulation cycles in 44 egg donors.
  
  
  METHODS
  Controlled ovarian hyperstimulation (COH) with GnRH antagonist protocol triggered with hCG or GnRH agonist (leuprolide acetate 0.15 mg) in the same egg donors in two consecutive cycles.
  
  
  METHODS
  The primary outcome measure was the proportion of mature and fertilized oocytes per donor cycle. Secondary outcome measures were implantation and pregnancy rates in the recipients and incidence of ovarian hyperstimulation syndrome (OHSS) in oocyte donors.
  
  
  RESULTS
  The proportion of mature oocytes, fertilized oocytes and mean embryo scores were comparable between the two triggering agents. While implantation (36.53% vs, 32.93%), pregnancy (69.08% vs. 68.81%) and clinical pregnancy (41.3% vs. 40.2%) rates were comparable for the groups, the incidence of OHSS was significantly lower in GnRH than in hCG triggered cycles.
  
  
  CONCLUSIONS
  Fertilization, implantation and pregnancy rates from donor oocytes stimulated with GnRH antagonist protocol were identical for donor cycles triggered with hCG and GnRH agonist. GnRH antagonist triggering in egg donors was associated with lower rates of OHSS.
authors.affiliation: Obstetrics & Gynecology, Assisted Reproduction Center, German Hospital and Bahceci Women's Health Care Center, Istanbul, Turkey. docalper@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Sismanoglu
authors.forename: H I
authors.initials: HI
authors.lastname: Tekin
authors.forename: H F
authors.initials: HF
authors.lastname: Erden
authors.forename: N H
authors.initials: NH
authors.lastname: Ciray
authors.forename: U
authors.initials: U
authors.lastname: Ulug
authors.forename: M
authors.initials: M
authors.lastname: Bahceci
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000819:agonists / Q000378:metabolism*; D018592:Cross-Over Studies; D005260:Female; D005306:Fertilization; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000378:metabolism*; D006801:Humans; D007246:Infertility / Q000628:therapy; D018587:Oocyte Donation; D016471:Ovarian Hyperstimulation Syndrome; D010060:Ovulation; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D006063:Chorionic Gonadotropin; D007987:Gonadotropin-Releasing Hormone